What Medarex Has To Offer At $2.4 Billion
Bristol-Myers Squibb's July 22 offer to buy Medarex for $2.4 billion seems to be a coup for the biotech. While most biotechs are struggling to raise money, Medarex enticed a suitor to pay nearly double its recent stock price
You may also be interested in...
The Trump Administration’s budget proposal aims to slash NIH funding that's critical to drug discovery and early research. Here’s a look at 20 of the 213 FDA-approved drugs that benefited from public grants, including IO pioneer Yervoy.
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.